HomeCompareCYT vs ADC

CYT vs ADC: Dividend Comparison 2026

CYT yields 66.23% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYT wins by $703.0K in total portfolio value
10 years
CYT
CYT
● Live price
66.23%
Share price
$3.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$880.0K
Annual income
$221,634.45
Full CYT calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — CYT vs ADC

📍 CYT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYT + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYT pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYT
Annual income on $10K today (after 15% tax)
$5,629.14/yr
After 10yr DRIP, annual income (after tax)
$188,389.28/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, CYT beats the other by $120,689.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYT + ADC for your $10,000?

CYT: 50%ADC: 50%
100% ADC50/50100% CYT
Portfolio after 10yr
$528.5K
Annual income
$150,640.84/yr
Blended yield
28.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

CYT
Analyst Ratings
2
Buy
1
Hold
2
Sell
Consensus: Buy
Price Target
$2.00
-33.8% upside vs current
Range: $2.00 — $2.00
Altman Z
9.4
Piotroski
1/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYT buys
0
ADC buys
0
No recent congressional trades found for CYT or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTADC
Forward yield66.23%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$880.0K$176.9K
Annual income after 10y$221,634.45$79,647.25
Total dividends collected$742.8K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$2.00$81.06

Year-by-year: CYT vs ADC ($10,000, DRIP)

YearCYT PortfolioCYT Income/yrADC PortfolioADC Income/yrGap
1← crossover$17,323$6,622.52$10,987$577.21+$6.3KCYT
2$29,256$10,721.37$12,293$855.34+$17.0KCYT
3$48,227$16,923.00$14,088$1,290.70+$34.1KCYT
4$77,675$26,071.48$16,660$1,994.91+$61.0KCYT
5$122,356$39,243.54$20,525$3,181.85+$101.8KCYT
6$188,694$57,773.40$26,654$5,286.90+$162.0KCYT
7$285,170$83,268.01$37,006$9,259.47+$248.2KCYT
8$422,742$117,609.16$55,862$17,338.74+$366.9KCYT
9$615,273$162,940.02$93,452$35,300.32+$521.8KCYT
10$879,977$221,634.45$176,931$79,647.25+$703.0KCYT

CYT vs ADC: Complete Analysis 2026

CYTStock

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Full CYT Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this CYT vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYT vs SCHDCYT vs JEPICYT vs OCYT vs KOCYT vs MAINCYT vs NNNCYT vs EPRTCYT vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.